Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

CRL Balance Sheet

Assets, liabilities, and equity analysis

CRL Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/28/2026
12/27/2025
09/27/2025
06/28/2025
03/29/2025
12/31/2024
09/28/2024
06/29/2024
Total Current Assets
1.489B1.489B1.447B1.532B1.470B1.506B1.403B1.495B1.499B
191.830M191.830M213.770M207.670M182.824M229.356M194.606M210.171M179.213M
Short-Term Investments
0.000.000.000.000.000.000.000.000.00
Cash & Short-Term Investments
191.830M191.830M213.770M207.670M182.824M229.356M194.606M210.171M179.213M
700.251M700.251M708.856M734.482M767.569M756.629M720.915M754.207M762.221M
359.723M359.723M299.103M302.550M279.550M290.156M278.544M336.200M349.111M
Total Assets
7.730B7.730B7.135B7.514B7.561B7.582B7.528B8.004B7.948B
1.828B1.828B2.017B1.966B1.992B1.990B2.017B2.025B2.000B
3.040B3.040B2.764B2.922B2.936B2.873B2.847B3.125B3.080B
Intangible Assets
248.989M248.989M339.995M571.094M602.452M655.705M723.400M778.461M800.129M
Long-Term Investments
209.723M209.723M206.972M196.185M216.073M214.026M218.350M235.987M231.859M
Total Current Liabilities
1.094B1.094B1.120B1.122B1.080B1.051B994.101M1.012B947.519M
133.952M133.952M148.800M169.615M145.798M149.334M140.337M135.963M133.101M
0.000.0061.057M2.636M0.000.000.000.000.00
Total Liabilities
4.742B4.742B3.924B4.063B4.161B4.341B4.020B4.176B4.175B
3.056B3.056B2.546B2.160B2.332B2.511B2.240B2.327B2.409B
3.056B3.056B3.066B2.631B2.786B2.986B2.724B2.759B2.838B
Net Debt (Cash)
2.864B2.864B2.852B2.424B2.603B2.757B2.529B2.549B2.659B
Total Shareholders' Equity
2.941B2.941B3.165B3.405B3.353B3.194B3.462B3.782B3.723B
Common Stock
493K493K492K514K513K512K511K517K517K
1.374B1.374B1.389B1.944B1.890B1.838B1.812B2.123B2.054B
1.361.361.291.371.361.431.411.481.58
1.041.040.970.770.830.930.790.730.76

CRL Annual Balance Sheet (USD)

Annual Report
12/27/2025
12/28/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Current Assets
1.447B1.403B1.609B1.439B1.274B1.201B1.021B897.836M
213.770M194.606M276.771M233.912M245.237M228.424M238.014M195.442M
Short-Term Investments
0.000.000.000.000.001.024M941K0.00
Cash & Short-Term Investments
213.770M194.606M276.771M233.912M246.300M229.448M238.955M195.442M
708.856M720.915M780.375M752.390M650.381M617.740M514.033M472.248M
299.103M278.544M380.259M255.809M199.146M185.695M160.660M127.892M
Total Assets
7.135B7.528B8.195B7.603B7.024B5.491B4.693B3.856B
2.017B2.017B2.034B1.857B1.584B1.303B1.184B932.877M
2.764B2.847B3.095B2.850B2.712B1.809B1.541B1.247B
Intangible Assets
339.995M723.400M864.051M955.275M1.061B787.599M689.413M610.888M
Long-Term Investments
206.972M218.350M243.811M311.602M201.352M221.804M122.979M88.591M
Total Current Liabilities
1.120B994.101M1.055B1.092B1.033B839.751M710.181M558.222M
148.800M140.337M168.937M205.915M198.130M122.475M111.498M66.250M
61.057M0.000.000.00101K47.196M35.548M31.416M
Total Liabilities
3.924B4.020B4.536B4.579B4.432B3.347B3.026B2.518B
2.546B2.240B2.647B2.708B2.917B1.901B1.822B1.637B
3.066B2.724B3.066B3.097B3.206B2.160B2.025B1.697B
Net Debt (Cash)
2.852B2.529B2.790B2.863B2.964B1.932B1.787B1.502B
Total Shareholders' Equity
3.165B3.462B3.597B2.976B2.535B2.115B1.635B1.317B
Common Stock
492K511K513K509K505K498K489K482K
1.389B1.812B1.887B1.433B980.751M625.414M280.329M42.096M
1.291.411.521.321.231.431.441.61
0.970.790.851.041.261.021.241.29

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster